Expression and clinical value of activating transcription factor-3 in endometrial serous carcinoma

Objects: To investigate the expression of activating transcription factor-3 (ATF3), its correlation with mutant-type p53 (MTP53) in endometrial serous carcinoma (ESC), and discuss the possible mechanism of its significance in this neoplasm. Materials and Methods: The clinical information of 33 patients aged 44-73 years, admitted to Yantai Yuhuangding hospital for surgical treatment of ESC between January 2003 and December 2013 were retrospectively reviewed. Immunohistochemistry analysis of ATF3 and MTP53 were performed on ESC and surrounding tissues. Correlation between ATF3 expression and the clinicopathological features of patients, MTP53 expression, and disease-free survival of patients were analyzed. Results: The expression ratio for ATF3 in ESC tissue (27.27%) was significantly lower than that in adjacent tissues (87.88%) (p < 0.01). There was no significant difference in positive ratio of ATF3 among each clinicopathological groups. The authors found a negative correlation between the ATF3 and MTP53 expression in ESC tissues. The three- and five-year disease-free survival rates for ATF3+ patients were both significantly higher than for ATF3-patients. Conclusions: ATF3 plays an important role in the tumorigenesis of ESC and is likely to be a prognostic factor for ESC.

Endometrial cancer; Serous carcinoma; Mutant type p53, MTP53; ATF3; Prognosis.

[1] SGO Clinical Practice Endometrial Cancer Working Group, Burke W.M., Orr J., Leitao M., Salom E., Gehrig P., et al.: “Endometrial cancer: a review and current management strategies: part I”. Gynecol. Oncol., 2014, 134, 385.

[2] Park J.Y., Nam J.H., Kim Y.T., Kim Y.M., Kim J.H., Kim D.Y., et al.: “Poor prognosis of uterine serous carcinoma compared with grade 3 endometrioid carcinoma in early stage patients”. Virchows Arch., 2013, 462, 289.

[3] Jhingran A., Ramondetta L.M., Bodurka D.C., Slomovitz B.M., Brown J., Levy L.B., et al.: “A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium”. Gynecol. Oncol., 2013, 129, 304.

[4] Bartosch C., Manuel Lopes J., Oliva E.: “Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features”. Adv. Anat. Pathol., 2011, 18, 415.

[5] Kovalev S., Marchenko N.D., Gugliotta B.G., Chalas E., Chumas J., Moll U.M.: “Loss of p53 function in uterine papillary serous carcinoma”. Hum. Pathol., 1998, 29, 613.

[6] King S.A., Adas A.A., LiVolsi V.A., Takahashi H., Behbakht K., Mc- Govern P., et al.: “Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma”. Cancer, 1995, 75, 2700.

[7] Zheng W., Cao P., Zheng M., Kramer E.E., Godwin T.A.: “p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes”. Gynecol. Oncol., 1996, 61, 167.

[8] Mo P., Wang H., Lu H., Boyd D.D., Yan C.: “MDM2 mediates ubiquitination and degradation of activating transcription factor 3”. J. Biol. Chem., 2010, 285, 26908.

[9] Oh Y.K., Lee H.J., Jeong M.H., Rhee M., Mo J.W., Song E.H., et al.: Role of activating transcription factor 3 on TAp73 stability and apoptosis in paclitaxel-treated cervical cancer cells”. Mol. Cancer Res., 2008, 6, 1232.

[10] Wei S., Wang H., Lu C., Malmut S., Zhang J., Ren S., Yu G., et al.: “The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins”. J. Biol. Chem., 2014, 289, 8947.

[11] Yuan X., Yu L., Li J., Xie G., Rong T., Zhang L., et al.: “ATF3 suppresses metastasis of bladder cancer by regulating gelsolin-mediated remodeling of the actin cytoskeleton”. Cancer Res., 2013, 73, 3625.

[12] Hackl C., Lang S.A., Moser C., Mori A., Fichtner-Feigl S., Hellerbrand C., et al.: “Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heatshock protein 90 (Hsp90) inhibition”. BMC Cancer, 2010, 10, 668.

[13] Beer D.G., Kardia S.L., Huang C.C., Giordano T.J., Levin A.M., Misek D.E.,et al.: “Gene-expression profiles predict survival of patients with lung adenocarcinoma”. Nat Med., 2002, 8, 816.

[14] Jan Y.H., Tsai H.Y., Yang C.J., Huang M.S., Yang Y.F., Lai T.C., et al.: “Adenylate kinase-4 is a marker of poor clinical outcomes that promotes metastasis of lung cancer by downregulating the transcription factor ATF3”. Cancer Res., 2012, 72, 5119.

[15] Cao H., Yang Z.X., Jiang G.Q.: “Expression and clinical significance of activating transcription factor 3 in human breast cancer”. Iran J. Basic Med Sci., 2013, 16, 1151.

[16] Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al.: “Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications”. Proc. Natl. Acad. Sci. USA, 2001, 98, 10869.

[17] Chen X., Cheung S.T., So S., Fan S.T., Barry C., Higgins J., et al.: “Gene expression patterns in human liver cancers”. Mol. Biol. Cell, 2002, 13, 1929.

[18] Oncology FCoG: “Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia”. Int. J. Gynaecol. Obstet., 2009, 105, 3.

[19] Kiernan J.A.: “Histological and histochemical methods: theory and practice”. 4thed. Bloxham, UK: Scion, 2008.

[20] Sun D.Z., Xu L., Wei P.K., Liu L., He J.: “Syndrome differentiation in traditional Chinese medicine and E-cadherin/ICAM-1 gene protein expression in gastric carcinoma”. World J Gastroenterol., 2007, 13, 4321.

[21] Kashiwakura Y., Ochiai K., Watanabe M., Abarzua F., Sakaguchi M., Takaoka M., et al.: “Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis”. Cancer Res., 2008, 68, 8333.

[22] Xie J.J., Xie Y.M., Chen B., Pan F., Guo J.C., Zhao Q., et al.: “ATF3 functions as a novel tumor suppressor with prognostic significance in esophageal squamous cell carcinoma”. Oncotarget, 2014, 5, 8569.

[23] Bottone F.G., Jr., Moon Y., Kim J.S., Alston-Mills B., Ishibashi M., Eling T.E.: “The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3)”. Mol. Cancer Ther., 2005, 4, 693.

[24] Ishiguro T., Nagawa H., Naito M., Tsuruo T.: “Inhibitory effect of ATF3 antisense oligonucleotide on ectopic growth of HT29 human colon cancer cells”. Jpn. J. Cancer Res., 2000, 91, 833.

[25] Wang H., Mo P., Ren S., Yan C.: “Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6”. J. Biol. Chem., 2010, 285, 13201.

[26] Chen N., Yi X., Abushahin N., Pang S., Zhang D., Kong B., Zheng W.: “Nrf2 expression in endometrial serous carcinomas and its precancers”. Int. J. Clin. Exp. Pathol., 2010, 4, 85.

[27] Brown S.L., Sekhar K.R., Rachakonda G., Sasi S., Freeman M.L.: “Activating transcription factor 3 is a novel repressor of the nuclear factor erythroid-derived 2-related factor 2 (Nrf2[)-regulated stress pathway”. Cancer Res., 2008, 68, 364.

[28] Chiste M., Alexis J., Recine M.: “IMP3 expression in serous tumors of the ovary”. Appl. Immunohistochem. Mol. Morphol., 2014, 22, 658.

[29] Damasceno E.A., Carneiro F.P., Magalhaes A.V., Carneiro Mde V., Takano G.H., Vianna L.M., et al.: “IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status”. J. Cancer Res. Clin. Oncol., 2014, 140, 2163.

[30] Szarvas T., Tschirdewahn S., Niedworok C., Kramer G., Sevcenco S., Reis H., et al.: “Prognostic value of tissue and circulating levels of IMP3 in prostate cancer”. Int. J. Cancer, 2014, 135, 1596.

[31] Li C., Zota V., Woda B.A., Rock K.L., Fraire A.E., Jiang Z., et al.: “Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations”. Mod. Pathol., 2007, 20, 1263.

[32] Shaco-Levy R., Sharabi S., Piura B., Sion-Vardy N.: “MMP-2, TIMP-1, E-cadherin, and beta-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium”. Acta Obstet. Gynecol. Scand., 2008, 87, 868.

[33] Yan C., Wang H., Boyd D.D.: “ATF3 represses 72-kDa type IV collagenase (MMP-2) expression by antagonizing p53-dependent trans-activation of the collagenase promoter”. J. Biol. Chem., 2002, 277, 10804.

[34] Chen H.H., Wang D.L.: “Nitric oxide inhibits matrix metalloproteinase- 2 expression via the induction of activating transcription factor 3 in endothelial cells”. Mol. Pharmacol., 2004, 65, 1130.

[35] Stearns M.E., Kim G., Garcia F., Wang M.: “Interleukin-10 induced activating transcription factor 3 transcriptional suppression of matrix metalloproteinase-2 gene expression in human prostate CPTX- 1532 Cells”. Mol. Cancer Res., 2004, 2, 403.

[36] Xiaoyan L., Shengbing Z., Yu Z., Lin Z., Chengjie L., Jingfeng L., Aimin H.: “Low expression of activating transcription factor 3 in human hepatocellular carcinoma and its clinicopathological significance”. Pathol. Res. Pract., 2014, 210, 477.

[37] Odicino F.E., Bignotti E., Rossi E., Pasinetti B., Tassi R.A., Donzelli C., et al.: “HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization”. Int. J. Gynecol. Cancer, 2008, 18, 14.

[38] Liang S., Mu K., Wang Y., Zhou Z., Zhang J., Sheng Y., Zhang T.: “CyclinD1, a prominent prognostic marker for endometrial diseases”. Diagn. Pathol., 2013, 8, 138.

[39] Yallowitz A.R., Li D., Lobko A., Mott D., Nemajerova A., Marchenko N., et al.: “Mutant p53 amplifies Epidermal Growth Factor Receptor family signaling to promote mammary tumorigenesis”. Mol. Cancer Res., 2015, 13, 743.

[40] Feng J., Sun Q., Wu T., Lu J., Qu L., Sun Y., et al.: “Upregulation of ATF-3 is correlated with prognosis and proliferation of laryngeal cancer by regulating Cyclin D1 expression”. Int. J. Clin. Exp. Pathol., 2013, 6, 2064.